Search results
Results from the WOW.Com Content Network
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Tuesday, Emergent BioSolutions Inc. (NYSE: ... This new procurement funding is from Emergent’s existing 10-year contract with the Biomedical Advanced Research and Development Authority.
An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled ...
(Reuters) -Emergent BioSolutions said on Thursday the U.S. Food and Drug Administration has approved its anthrax vaccine for use in adults aged 18 through 65. The vaccine, Cyfendus, has been ...
El-Hibri was the Emergent BioSolutions board of directors executive chairman from April 2012 until shortly before his death. He was both the board chairman and the CEO of the company from 2004 to 2012. He was the board chairman and CEO of BioPort Corporation from 1998 to 2004. Emergent acquired BioPort in 2004. [3]
Kanatzhan "Kanat" Baizakovich Alibekov [1] (born 1950), known as Kenneth "Ken" Alibek [2] since 1992, is a Kazakh-American microbiologist, bioweaponeer, and biological warfare administrative management expert.
(Reuters) - Drugmaker Emergent BioSolutions said on Monday that it would reduce its workforce in Lansing, Michigan, by up to 70 roles as part of its ongoing restructuring efforts.
After the February 2014 acquisition of Cangene Corporation by Emergent BioSolutions, Emergent took control of Cangene's products and contracts, including BAT. [12] In March 2017, Emergent extended its contract with the Biomedical Advanced Research and Development Authority (BARDA), adding $53 million in value throughout 2022 for the production ...